Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Renal cell carcinoma (RCC) is chemoresistant cancer. In this study, we explored the candidates of novel therapeutic medications for RCC. The 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an endogenous anti-cancerous agent. Treatment with low concentrations at which cell death does not occur, of 15d-PGJ2 decreased the migration of Caki-2 cells. The von Hippel-Lindau (VHL) gene is closely associated with the onset of kidney cancer. 15d-PGJ2 enhanced the effect of anti-cancer agents independently of VHL status in renal cell carcinomas.
|